{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:39:02Z","timestamp":1791517142475,"version":"4.3.4"},"reference-count":81,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,17]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Richter transformation (RT) is defined as an aggressive lymphoma emerging in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL). Despite novel therapeutics developed in CLL, RT is associated with poor outcomes. In light of recent progress regarding the diagnostic procedures and therapeutic concepts of RT, an international group of experts, under the coordination of the European Research Initiative on CLL, has developed consensus recommendations for clinical procedures and future research on this disease. Patients with RT typically present with a rapid clinical decline, worsening B-symptoms, elevated lactate dehydrogenase, and\/or rapidly enlarging lymphadenopathy. Workup should include a positron emission tomography\u2013computed tomography scan for patients with suspected RT. An excisional biopsy should be taken from an accessible lesion, preferably with the highest fluorodeoxyglucose avidity, and analyzed for the presence of aggressive lymphoma. The molecular relationship to the original CLL clone(s) should be defined. Because no effective standard treatment for RT exists, patients should be treated in a clinical trial. Response of both RT and CLL should be assessed at an early time point, and survival end points should be prioritized in trial design. We hope that these recommendations can help to harmonize clinical and translational research and improve outcomes for patients with RT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024028064","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T16:00:03Z","timestamp":1744819203000},"page":"291-303","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations"],"prefix":"10.1182","volume":"146","author":[{"given":"Adam S.","family":"Kittai","sequence":"first","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Marchetti","sequence":"additional","affiliation":[{"name":"2Hematology and Transplant Center, Azienda Ospedaliera Universitaria SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othman","family":"Al-Sawaf","sequence":"additional","affiliation":[{"name":"3Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohad","family":"Benjamini","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Ramat Gan, Israel"},{"name":"5Faculty of Medical and Health Sciences, School of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[{"name":"6City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[{"name":"7Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Eichhorst","sequence":"additional","affiliation":[{"name":"3Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[{"name":"8Haematology and Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2587-7901","authenticated-orcid":false,"given":"Anna Maria","family":"Frustaci","sequence":"additional","affiliation":[{"name":"9Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"3Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1292-3024","authenticated-orcid":false,"given":"Paul J.","family":"Hampel","sequence":"additional","affiliation":[{"name":"10Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Herishanu","sequence":"additional","affiliation":[{"name":"11Faculty of Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-0824","authenticated-orcid":false,"given":"Rodney J.","family":"Hicks","sequence":"additional","affiliation":[{"name":"12Department of Medicine, The University of Melbourne, St Vincent\u2019s Hospital, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-1891","authenticated-orcid":false,"given":"Arnon P.","family":"Kater","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Cancer Center Amsterdam, Lymmcare, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"King","sequence":"additional","affiliation":[{"name":"14Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose I.","family":"Martin-Subero","sequence":"additional","affiliation":[{"name":"15Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, University of Barcelona, Barcelona, Spain"},{"name":"16Instituci\u00f3 Catalana de Recerca i Estudis Avan\u00e7ats, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Owen","sequence":"additional","affiliation":[{"name":"17Division of Hematology and Hematological Malignancies, University of Calgary, Calgary, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-9769","authenticated-orcid":false,"given":"Erin","family":"Parry","sequence":"additional","affiliation":[{"name":"7Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurilio","family":"Ponzoni","sequence":"additional","affiliation":[{"name":"18Pathology Unit and Unit of Lymphoid Malignancies, IRCCS Ospedale San Raffaele, Milan, Italy"},{"name":"19Medical School, Universit\u00e0 Vita-Salute San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[{"name":"20Clinic of Hematology, Oncology Institute of Southern Switzerland, Laboratory of Hematology, Institute of Oncology Research, Universit\u00e0 Della Svizzera Italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5292-8298","authenticated-orcid":false,"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"6City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[{"name":"21Division of Chronic Lymphocytic Leukaemia, Department of Internal Medicine III and Comprehensive Cancer Center, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"22Alfred Hospital and Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa ten","family":"Hacken","sequence":"additional","affiliation":[{"name":"23Division of Hematology\/Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-6031","authenticated-orcid":false,"given":"Philip A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"24Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"25The Sir Peter MacCallum Department of Clinical Oncology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wierda","sequence":"additional","affiliation":[{"name":"26Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4681-0151","authenticated-orcid":false,"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[{"name":"27Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-9144","authenticated-orcid":false,"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"28Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-7342","authenticated-orcid":false,"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[{"name":"19Medical School, Universit\u00e0 Vita-Salute San Raffaele, Milan, Italy"},{"name":"29Strategic Research Program on Chronic Lymphocytic Leukaemia, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2025071711214788000_bib1","volume-title":"WHO Classification of Tumors of Haematopoetic and Lymphoid Tissues","author":"Swerdlow","year":"2017","edition":"Revised 4th ed"},{"issue":"2","key":"2025071711214788000_bib2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"2025071711214788000_bib3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2025071711214788000_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Al-Sawaf","year":"2021","journal-title":"Leukemia"},{"key":"2025071711214788000_bib5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.canep.2019.04.002","article-title":"Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway","volume":"60","author":"Lenartova","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"2025071711214788000_bib6","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"key":"2025071711214788000_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jclinepi.2021.09.028","article-title":"A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations","volume":"141","author":"Lotfi","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2025071711214788000_bib8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2025071711214788000_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: How to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"issue":"1","key":"2025071711214788000_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-025-01236-6","article-title":"Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL","volume":"15","author":"Kittai","year":"2025","journal-title":"Blood Cancer J"},{"issue":"19","key":"2025071711214788000_bib11","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"2025071711214788000_bib12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med Overseas Ed"},{"issue":"2","key":"2025071711214788000_bib13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"10232","key":"2025071711214788000_bib14","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial [published correction appears in Lancet. 2020;395(10238):1694]","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"2025071711214788000_bib15","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"2025071711214788000_bib16","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/leu.2017.246","article-title":"Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group","volume":"31","author":"Hoechstetter","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2025071711214788000_bib17","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/s41375-020-0747-7","article-title":"Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial","volume":"34","author":"Herling","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"2025071711214788000_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood.2021010845","article-title":"The CLL12 trial: ibrutinib vs placebo in treatment-na\u00efve, early-stage chronic lymphocytic leukemia","volume":"139","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"issue":"19","key":"2025071711214788000_bib19","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/bloodadvances.2017007302","article-title":"Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib","volume":"1","author":"Miller","year":"2017","journal-title":"Blood Adv"},{"issue":"15","key":"2025071711214788000_bib20","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2025071711214788000_bib21","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3324\/haematol.2021.278304","article-title":"The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation","volume":"107","author":"Visentin","year":"2022","journal-title":"Haematologica"},{"issue":"2","key":"2025071711214788000_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","article-title":"Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"142","author":"Rossi","year":"2008","journal-title":"Br J Haematol"},{"issue":"13","key":"2025071711214788000_bib23","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","article-title":"Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2025071711214788000_bib24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09155.x","article-title":"Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"158","author":"Rossi","year":"2012","journal-title":"Br J Haematol"},{"issue":"11","key":"2025071711214788000_bib25","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.3324\/haematol.2019.231027","article-title":"Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)","volume":"105","author":"Jaramillo","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2025071711214788000_bib26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.26755","article-title":"Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"98","author":"Kittai","year":"2023","journal-title":"Am J Hematol"},{"issue":"15","key":"2025071711214788000_bib27","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J Clin Oncol"},{"issue":"27","key":"2025071711214788000_bib28","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group [published correction appears in J Clin Oncol. 2016;34(21):2562]","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"issue":"27","key":"2025071711214788000_bib29","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"21","key":"2025071711214788000_bib30","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","article-title":"Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma","volume":"23","author":"Sch\u00f6der","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025071711214788000_bib31","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1182\/bloodadvances.2023011566","article-title":"Utility of FDG-PET in predicting the histology of relapsed or refractory lymphoma","volume":"8","author":"Wai","year":"2024","journal-title":"Blood Adv"},{"issue":"18","key":"2025071711214788000_bib32","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","article-title":"Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia","volume":"123","author":"Falchi","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2025071711214788000_bib33","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3109\/10428194.2015.1099643","article-title":"An 18F-FDG-PET maximum standardized uptake value &gt; 10 represents a novel valid marker for discerning Richter's Syndrome","volume":"57","author":"Michallet","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2025071711214788000_bib34","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3109\/10428194.2013.802313","article-title":"2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation","volume":"55","author":"Papaj\u00edk","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2025071711214788000_bib35","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.3324\/haematol.2018.207068","article-title":"Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy","volume":"104","author":"Mato","year":"2019","journal-title":"Haematologica"},{"issue":"8","key":"2025071711214788000_bib36","first-page":"1267","article-title":"Detection of Richter's transformation of chronic lymphocytic leukemia by PET\/CT","volume":"47","author":"Bruzzi","year":"2006","journal-title":"J Nucl Med"},{"issue":"11","key":"2025071711214788000_bib37","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3324\/haematol.2019.240564","article-title":"The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"2025071711214788000_bib38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.6004\/jnccn.2024.0018","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Wierda","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"2025071711214788000_bib39","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2025071711214788000_bib40","doi-asserted-by":"crossref","first-page":"100466","DOI":"10.1016\/j.modpat.2024.100466","article-title":"Fifth edition of the World Health Organization classification of tumors of the hematopoietic and lymphoid tissues: acute lymphoblastic leukemias, mixed-phenotype acute leukemias, myeloid\/lymphoid neoplasms with eosinophilia, dendritic\/histiocytic neoplasms, and genetic tumor syndromes","volume":"37","author":"Choi","year":"2024","journal-title":"Mod Pathol"},{"issue":"6","key":"2025071711214788000_bib41","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/his.13024","article-title":"Diagnostic dilemmas of high-grade transformation (Richter's syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review","volume":"69","author":"Soilleux","year":"2016","journal-title":"Histopathology"},{"issue":"18","key":"2025071711214788000_bib42","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","article-title":"Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network","volume":"35","author":"Laurent","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025071711214788000_bib43","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3324\/haematol.2010.022277","article-title":"Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (\"accelerated\" chronic lymphocytic leukemia) with aggressive clinical behavior","volume":"95","author":"Gin\u00e9","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"2025071711214788000_bib44","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1111\/bjh.16948","article-title":"Pseudo-Richter transformation of chronic lymphocytic leukaemia\/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall","volume":"191","author":"Barnea Slonim","year":"2020","journal-title":"Br J Haematol"},{"issue":"18","key":"2025071711214788000_bib45","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/bloodadvances.2020002454","article-title":"Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib","volume":"4","author":"Hampel","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2025071711214788000_bib46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41467-022-34642-6","article-title":"Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis","volume":"14","author":"Bros\u00e9us","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"2025071711214788000_bib47","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","article-title":"Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome","volume":"29","author":"Parry","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"2025071711214788000_bib48","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1158\/2643-3230.BCD-22-0082","article-title":"In vivo modeling of CLL transformation to Richter syndrome reveals convergent evolutionary paths and therapeutic vulnerabilities","volume":"4","author":"Ten Hacken","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"20","key":"2025071711214788000_bib49","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2020005650","article-title":"Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia","volume":"137","author":"Klintman","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2025071711214788000_bib50","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"2025071711214788000_bib51","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2025071711214788000_bib52","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","article-title":"Biology and treatment of Richter syndrome","volume":"131","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2025071711214788000_bib53","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41375-022-01604-2","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL","volume":"36","author":"Agathangelidis","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"2025071711214788000_bib54","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41375-024-02163-4","article-title":"Updates of the ERIC recommendations on how to report the results from immunoglobulin heavy variable gene analysis in chronic lymphocytic leukemia","volume":"38","author":"Chatzikonstantinou","year":"2024","journal-title":"Leukemia"},{"issue":"7","key":"2025071711214788000_bib55","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/PAS.0000000000001077","article-title":"PD-1 expression in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and large B-cell Richter transformation (DLBCL-RT): a characteristic feature of DLBCL-RT and potential surrogate marker for clonal relatedness","volume":"42","author":"He","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"2025071711214788000_bib56","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00277-021-04603-y","article-title":"Outcomes of Richter\u2019s transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an analysis of the SEER database","volume":"100","author":"Elnair","year":"2021","journal-title":"Ann Hematol"},{"key":"2025071711214788000_bib57","doi-asserted-by":"crossref","first-page":"1295293","DOI":"10.3389\/fimmu.2023.1295293","article-title":"Response to therapy in Richter syndrome: a systematic review with meta-analysis of early clinical trials","volume":"14","author":"Sousa-Pimenta","year":"2023","journal-title":"Front Immunol"},{"issue":"suppl 1","key":"2025071711214788000_bib58","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2021-147146","article-title":"Real world data on the outcomes of Richter's transformation of chronic lymphocytic leukemia and small lymphocytic lymphoma in the Australian population: an Australasian Lymphoma Alliance study [abstract]","volume":"138","author":"Walker","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2025071711214788000_bib59","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1182\/blood-2022-155950","article-title":"Predictors of adverse clinical outcome in diffuse large B-cell lymphoma Richter transformation of CLL\/SLL: a Consortium of Richter Transformation Investigators (CORTI) multicenter study across 8 US, UK, and Australian academic centers [abstract]","volume":"140","author":"Symes","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2025071711214788000_bib60","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjh.16748","article-title":"Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)","volume":"190","author":"Abrisqueta","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"2025071711214788000_bib61","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/RLU.0000000000002879","article-title":"Prognostic value of baseline total metabolic tumor volume measured on FDG PET in patients with Richter syndrome","volume":"45","author":"Pontoizeau","year":"2020","journal-title":"Clin Nucl Med"},{"issue":"9","key":"2025071711214788000_bib62","doi-asserted-by":"crossref","first-page":"E311","DOI":"10.1002\/ajh.26239","article-title":"Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: a study of the French Innovative Leukemia Organization","volume":"96","author":"Moulin","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"2025071711214788000_bib63","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/10428194.2020.1719092","article-title":"Richter's transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study","volume":"61","author":"Ben-Dali","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2025071711214788000_bib65","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"2025071711214788000_bib66","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14177","article-title":"NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome","volume":"175","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"issue":"8","key":"2025071711214788000_bib67","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","article-title":"Detection of early seeding of Richter transformation in chronic lymphocytic leukemia","volume":"28","author":"Nadeu","year":"2022","journal-title":"Nat Med"},{"issue":"10","key":"2025071711214788000_bib68","first-page":"1405","article-title":"Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma","volume":"91","author":"Rossi","year":"2006","journal-title":"Haematologica"},{"issue":"12","key":"2025071711214788000_bib69","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"2025071711214788000_bib70","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13039-023-00662-0","article-title":"Cytogenomic features of Richter transformation","volume":"16","author":"Woroniecka","year":"2023","journal-title":"Mol Cytogenet"},{"issue":"25","key":"2025071711214788000_bib71","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"21","key":"2025071711214788000_bib72","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2025071711214788000_bib73","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"suppl 1","key":"2025071711214788000_bib74","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2022-160465","article-title":"Immuno-genetic changes underlie response to immune checkpoint blockade therapy in Richter's syndrome mouse models [abstract]","volume":"140","author":"Ten Hacken","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025071711214788000_bib75","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41467-022-35778-1","article-title":"Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter\u2019s transformation","volume":"14","author":"Hing","year":"2023","journal-title":"Nat Commun"},{"key":"2025071711214788000_bib76","article-title":"Evolutionary dynamics of 1,976 lymphoid malignancies predict clinical outcome","author":"Gabbutt","year":"10  2023","journal-title":"medRxiv"},{"issue":"1","key":"2025071711214788000_bib77","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41591-023-02722-9","article-title":"Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial","volume":"30","author":"Al-Sawaf","year":"2024","journal-title":"Nat Med"},{"issue":"9","key":"2025071711214788000_bib78","doi-asserted-by":"crossref","first-page":"e682","DOI":"10.1016\/S2352-3026(24)00172-8","article-title":"Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1\/2 BRUIN study","volume":"11","author":"Wierda","year":"2024","journal-title":"Lancet Haematol"},{"issue":"5","key":"2025071711214788000_bib79","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood.2021011386","article-title":"Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome","volume":"139","author":"Davids","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2025071711214788000_bib80","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1182\/bloodadvances.2023012080","article-title":"A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia","volume":"8","author":"Hampel","year":"2024","journal-title":"Blood Adv"},{"issue":"17","key":"2025071711214788000_bib81","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1200\/JCO.24.00033","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy for Richter transformation: an international, multicenter, retrospective study","volume":"42","author":"Kittai","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"2025071711214788000_bib82","first-page":"3566","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma","volume":"109","author":"Benjamini","year":"2024","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/3\/291\/2403220\/blood_bld-2024-028064-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/3\/291\/2403220\/blood_bld-2024-028064-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T15:21:58Z","timestamp":1752765718000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/3\/291\/536756\/International-consensus-statement-on-diagnosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024028064","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,17]]},"published":{"date-parts":[[2025,7,17]]}}}